A stochastic model for primary HIV infection: optimal timing of therapy

被引:30
作者
Ribeiro, RM
Bonhoeffer, S
机构
[1] Friedrich Miescher Inst, CH-4002 Basel, Switzerland
[2] Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol & Infect Dis, Oxford OX1 3PS, England
[3] ETH Zentrum, Inst Expt Ecol, CH-8092 Zurich, Switzerland
基金
英国惠康基金;
关键词
primary infection; resistant mutant; stochastic model; timing of therapy;
D O I
10.1097/00002030-199902250-00007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To investigate the optimal time point for the initiation of therapy in HIV infection from the perspective of drug resistance. Background: The enormous genetic diversity of HIV within an infected individual represents one of the greatest challenges for effective therapy, because the viral population may harbour drug-resistant mutants that rapidly outgrow the wild-type virus once the patient starts treatment. To determine the optimal timing of therapy it is crucial to know how long it takes for the viral population to build up sufficient diversity to enable the virus to escape from therapy. Method: A stochastic model of the viral diversification during primary infection was used to study the behaviour of small population sizes of mutant virus. Results and conclusions: The simulations suggest that from the perspective of viral diversity, therapy should be started at the viral set-point. Starting treatment earlier involves a risk of the selective outgrowth of drug-resistant mutants, which are transiently present at the viral peak during primary infection. (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:351 / 357
页数:7
相关论文
共 38 条
[21]   SELECTION AND ANALYSIS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-I VARIANTS WITH INCREASED RESISTANCE TO ABT-538, A NOVEL PROTEASE INHIBITOR [J].
MARKOWITZ, M ;
MO, HM ;
KEMPF, DJ ;
NORBECK, DW ;
BHAT, TN ;
ERICKSON, JW ;
HO, DD .
JOURNAL OF VIROLOGY, 1995, 69 (02) :701-706
[22]   Antiretroviral therapy for HIV infection - A knowledge-based approach to drug selection and use [J].
Moyle, GJ ;
Gazzard, BG ;
Cooper, DA ;
Gatell, J .
DRUGS, 1998, 55 (03) :383-404
[23]   Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection [J].
Nowak, MA ;
Lloyd, AL ;
Vasquez, GM ;
Wiltrout, TA ;
Wahl, LM ;
Bischofberger, N ;
Williams, J ;
Kinter, A ;
Fauci, AS ;
Hirsch, VM ;
Lifson, JD .
JOURNAL OF VIROLOGY, 1997, 71 (10) :7518-7525
[24]   Population dynamics of immune responses to persistent viruses [J].
Nowak, MA ;
Bangham, CRM .
SCIENCE, 1996, 272 (5258) :74-79
[25]   The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia [J].
Pantaleo, G ;
Demarest, JF ;
Schacker, T ;
Vaccarezza, M ;
Cohen, OJ ;
Daucher, M ;
Graziosi, C ;
Schnittman, SS ;
Quinn, TC ;
Shaw, GM ;
Perrin, L ;
Tambussi, G ;
Lazzarin, A ;
Sekaly, RP ;
Soudeyns, H ;
Corey, L ;
Fauci, AS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (01) :254-258
[26]   Decay characteristics of HIV-1-infected compartments during combination therapy [J].
Perelson, AS ;
Essunger, P ;
Cao, YZ ;
Vesanen, M ;
Hurley, A ;
Saksela, K ;
Markowitz, M ;
Ho, DD .
NATURE, 1997, 387 (6629) :188-191
[27]  
Perrin L, 1995, J ACQ IMMUN DEF SYND, V10, pS69
[28]   Combined therapy with zidovudine and L-697,661 in primary HIV infection [J].
Perrin, L ;
Rakik, A ;
Yerly, S ;
Baumberger, C ;
KinlochdeLoes, S ;
Pechere, M ;
Hirschel, B .
AIDS, 1996, 10 (11) :1233-1237
[29]   Reduction of HIV concentration during acute infection: Independence from a specific immune response [J].
Phillips, AN .
SCIENCE, 1996, 271 (5248) :497-499
[30]   VIROLOGICAL CHARACTERIZATION OF PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION IN A HEALTH-CARE WORKER FOLLOWING NEEDLESTICK INJURY [J].
PRATT, RD ;
SHAPIRO, JF ;
MCKINNEY, N ;
KWOK, S ;
SPECTOR, SA .
JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (03) :851-854